Following the expansion of its research facility in Hyderabad at a cost of $25 million last year, the US Pharmacopeia (USP) is now focusing on new initiatives, including exploring public-private-partnership (PPP) opportunities in India.
US Pharmacopeia , a not-for-profit organisation that develops reference standards for drugs being made by pharmaceutical companies, is examining the public-private partnership projects being offered by the Union ministry of chemicals in the areas of establishing drug testing laboratories and chemical testing, according to Srini Srinivasan, executive vice-president of USP. He said that the USP was keen to take part in such initiatives funded by the government.
Terming quality standards as the core issue involving the larger interests of the public, he said the USP was willing to work with companies in India in achieving high standards in making the drugs.
Stating that the biologic products are going to be the future, Srinivasan said about $90 billion worth of biologic pharma products were going off-patent in the next three years, giving a huge opportunity to the generics manufacturers.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
